BRT-DA01 - 48 hours later
About two days after writing some about the importance of improving upon upstream biomanufacturing capacity with a product like Cellevates nanofiber microcarriers to support gene and cell therapy programs, Bluerock (a subsidiary of Bayer) announced the initiation of a phase-3 for BRT-DA01. The progression of this trial to a P3 status is promising. It’s the first of ClearPoint Neuro’s P3 trials for major indications that I’m aware of.
You can read about it here if you didn’t:
